Your browser doesn't support javascript.
loading
Proteomics-Based Regression Model for Assessing the Development of Chronic Lymphocytic Leukemia.
Bakhtina, Varvara I; Veprintsev, Dmitry V; Zamay, Tatiana N; Demko, Irina V; Mironov, Gleb G; Berezovski, Maxim V; Petrova, Marina M; Kichkailo, Anna S; Glazyrin, Yury E.
Afiliación
  • Bakhtina VI; Department of Hematology, Krasnoyarsk Regional Clinical Hospital, 660022 Krasnoyarsk, Russia.
  • Veprintsev DV; Laboratory for Digital Controlled Drugs and Theranostics, Federal Research Center "Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Science", 660036 Krasnoyarsk, Russia.
  • Zamay TN; Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University named after prof. V.F. Voyno-Yasenetsky, 660022 Krasnoyarsk, Russia.
  • Demko IV; Department of Hematology, Krasnoyarsk Regional Clinical Hospital, 660022 Krasnoyarsk, Russia.
  • Mironov GG; Faculty of Medicine, Krasnoyarsk State Medical University named after prof. V.F. Voyno-Yasenetsky, 660022 Krasnoyarsk, Russia.
  • Berezovski MV; Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N6N5, Canada.
  • Petrova MM; Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N6N5, Canada.
  • Kichkailo AS; Faculty of Medicine, Krasnoyarsk State Medical University named after prof. V.F. Voyno-Yasenetsky, 660022 Krasnoyarsk, Russia.
  • Glazyrin YE; Laboratory for Digital Controlled Drugs and Theranostics, Federal Research Center "Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Science", 660036 Krasnoyarsk, Russia.
Proteomes ; 9(1)2021 Jan 23.
Article en En | MEDLINE | ID: mdl-33498752
The clinical course of chronic lymphocytic leukemia (CLL) is very ambiguous, showing either an indolent nature of the disease or having latent dangerous progression, which, if diagnosed, will require an urgent therapy. The prognosis of the course of the disease and the estimation of the time of therapy initiation are crucial for the selection of a successful treatment strategy. A reliable estimating index is needed to assign newly diagnosed CLL patients to the prognostic groups. In this work, we evaluated the comparative expressions of proteins in CLL blood cells using a label-free quantification by mass spectrometry and calculated the integrated proteomic indexes for a group of patients who received therapy after the blood sampling over different periods of time. Using a two-factor linear regression analysis based on these data, we propose a new pipeline for evaluating model development for estimation of the moment of therapy initiation for newly diagnosed CLL patients.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Proteomes Año: 2021 Tipo del documento: Article País de afiliación: Rusia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Proteomes Año: 2021 Tipo del documento: Article País de afiliación: Rusia